4basebio partners with Circio to build and test circVec synthetic DNA vectors for genetic medicine and vaccines
· 4basebio and Circio are combining Circio´s circVec circular RNA expression system with 4basebio´s proprietary synthetic DNA formats hpDNA™ and opDNA™ · 4basebio´s unique nanoparticle delivery platform, Hermes™, allows for improved delivery of synthetic DNA vectors over conventional LNPs · Circio´s circVec technology has shown enhanced expression level and durability vs. standard mRNA approach, and together the technologies are expected to create a powerful therapeutic combinationOslo, Norway 21 January 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing